Arthroplasty, Replacement Clinical Trial
Official title:
A Randomized, Multi-Center, Prospective, Safety and Efficacy Study Comparing the Outcome of Total Reverse Shoulder Arthroplasty (RSA) With SMR Stemless Reverse vs SMR Reverse Shoulder System
The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function. This is a prospective, multi-center, randomized, controlled trial to demonstrate non-inferiority of the SMR Stemless Reverse to the SMR Reverse Shoulder System. Patients with joint dysfunction who continue to experience significant symptoms despite an appropriate course of non-operative management are eligible. Patients will be considered enrolled into the study when an ICF has been signed, all inclusion criteria are met and no exclusion criteria are present including intraoperative exclusion criteria, and the patient is randomized into either the SMR Stemless Reverse (investigational) group, the SMR Reverse Shoulder System (control) group or is part of the roll-in population. Enrollment is expected to take approximately 24 months.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02728661 -
Patient-Centered Weight Loss Program for Knee Replacement Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04080401 -
Effectiveness of a Novel Gaming System on Post-operative Rehabilitation Outcomes After Total Knee Arthroplasty
|
N/A | |
| Completed |
NCT02648958 -
Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations
|
N/A | |
| Completed |
NCT00846807 -
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
|
N/A | |
| Completed |
NCT04372173 -
An Evaluation of Clotting Factor Activity Before and After Total Hip Arthroplasty
|
||
| Recruiting |
NCT01909375 -
American Joint Replacement Registry
|
||
| Terminated |
NCT01153698 -
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
|
||
| Completed |
NCT01184989 -
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
|
Phase 4 | |
| Active, not recruiting |
NCT00114036 -
Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)
|
N/A | |
| Completed |
NCT03407885 -
The Impact of Medicare Bundled Payments
|
N/A | |
| Completed |
NCT01857349 -
Efficacy of Surgical Preparation Solutions in Knee Surgery
|
N/A | |
| Completed |
NCT00847301 -
Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
|
N/A | |
| Completed |
NCT03158623 -
Wound Additives in Primary Total Joint Athroplasty
|
Phase 3 |